Abbott Laboratories Inc. (ABT), a diversified healthcare company, is slated to report its first-quarter earnings for 2009 on Wednesday before the market opens. The company continues to benefit from the expanding uses of its lead arthritis drug Humira and the U.S. launch of Xience V, a profitable drug-coated stent.
Analysts tracked by Thomson Reuters expect the company to earn $0.70 per share on revenue of $7.06 billion for the quarter.
In the first quarter of 2008, Abbott's net earnings climbed to $937.8 million or $0.60 per share from $697.5 million or $0.45 per share in the comparable quarter a year before. Quarterly net sales were $6.76 billion, up from $5.95 billion a year before.
Last year, Humira raked in $4.5 billion in global sales and the company expects the drug's worldwide sales to increase more than 25% in 2009. Humira, which was originally approved by the FDA for rheumatoid arthritis in 2003, has since been approved for five additional indications.
According to Abbott, Xience V, which was launched in July 2008 in the U.S., has gained significant market share and it was the market-leading drug eluting stent in the U.S. in the fourth quarter of 2008.
Seeking to expand its growing medical device business, early this year, Abbott acquired Advanced Medical Optics for $22 per share in cash, for a total transaction value of approximately $2.8 billion, inclusive of estimated net debt at the time of closing. Globally, Advanced Medical Optics holds the number one position in LASIK surgical devices, the number two position in the cataract surgical device market and the number three position in contact lens care products. The transaction is expected to be neutral to ongoing earnings per share in 2009 and accretive beginning in 2010.
Abbott Labs has been building on its cholesterol-lowering franchise and consolidating its position with the acquisition of Kos Pharmaceuticals. The acquisition of Kos Pharma in 2006 for $3.7 billion helped Abbott add Kos' cholesterol-lowering drugs Niaspan (niacin) and Advicor (niacin plus lovastatin) to its arsenal. The company also gained the rights to another cholesterol-lowering medication Simcor, a new combination pill. Late last year, the FDA cleared Abbott's cholesterol drug TriLipix, the first fibrate to be combined with a statin for treating unhealthy cholesterol levels.
Abbott and British drug maker AstraZeneca plc (AZN) are working together to develop a fixed-dose combination of TriLipix and Crestor (rosuvastatin calcium). Crestor is AstraZeneca's blockbuster cholesterol drug. The companies plan to submit a new drug application for the combo drug to the FDA in the second half of 2009. The companies also have an agreement to co-promote rosuvastatin calcium in the United States.
Last month, the company said it will start enrolling patients for the second phase of its revolutionary fully bioabsorbable drug eluting stent study dubbed ABSORB in the first half of 2009. Results from the first stage of the ABSORB trial with 30 patients demonstrated that Abbott's bioabsorbable everolimus eluting stent successfully treated coronary artery disease, and that at two years, the treated vessel was able to expand and contract, without being restricted by a permanent implant - indicating that the device was absorbed.
While Humira and Xience V could have a positive impact on the company's performance, the generic competition to its seizure drug Depakote, which began in the second half of 2008, could continue to weigh on the company's results.
According to Morgan Stanley analyst David Lewis, as more patients lost health care coverage, Humira sales in the first-quarter could be less than expected.
On April 6, Wachovia downgraded Abbott to "Market Perform" from "Outperform" saying that the company's cholesterol franchise faced challenges and that the sales growth of its lead drug Humira is likely to slow in the future.
ABT has been trading in the range of $42.62 - $59.95 over the past 52 weeks. The stock closed Tuesday's trade at $44.71, up 0.74% on a volume of 13.6 million shares.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.